77 related articles for article (PubMed ID: 21383342)
1. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
Ibrahim T; Di Paolo A; Amatori F; Mercatali L; Ravaioli E; Flamini E; Sacanna E; Del Tacca M; Danesi R; Amadori D
J Clin Pharmacol; 2012 Mar; 52(3):361-9. PubMed ID: 21383342
[TBL] [Abstract][Full Text] [Related]
2. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
7. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Boisdron-Celle M; Craipeau C; Brienza S; Delva R; Guérin-Meyer V; Cvitkovic E; Gamelin E
Cancer Chemother Pharmacol; 2002 Mar; 49(3):235-43. PubMed ID: 11935216
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Woloch C; Di Paolo A; Marouani H; Bocci G; Ciccolini J; Lacarelle B; Danesi R; Iliadis A
Curr Top Med Chem; 2012; 12(15):1713-9. PubMed ID: 22978343
[TBL] [Abstract][Full Text] [Related]
9. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
10. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
11. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
12. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
13. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
17. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
[TBL] [Abstract][Full Text] [Related]
20. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]